第 1 到 17 筆結果,共 17 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2020 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer | WEN-CHI YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU ; ZHONG-ZHE LIN ; Lu S.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; SUNG-HSIN KUO | Clinical and Translational Radiation Oncology | 11 | 8 | |
2 | 2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
3 | 2019 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations | YEN-TING LIN ; JIN-SHING CHEN ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; Yang C.-Y.; KUAN-YU CHEN ; JIH-HSIANG LEE ; ZHONG-ZHE LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | International Journal of Cancer | 53 | 46 | |
4 | 2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
5 | 2015 | The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases | YUN CHIANG ; CHIH-HSIN YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; KENG-HSUEH LAN ; ANN-LII CHENG ; SUNG-HSIN KUO | PLoS ONE | 9 | 9 | |
6 | 2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 | |
7 | 2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
8 | 2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
9 | 2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
10 | 2012 | Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study | ZHONG-ZHE LIN ; Shau W.-Y.; YU-YUN SHAO ; Yang Y.-Y.; Kuo R.N.-C.; CHIH-HSIN YANG ; Laie M.-S. | Oncologist | 11 | 9 | |
11 | 2012 | Survival of patients with small cell lung carcinoma in Taiwan | Kuo Y.-H.; ZHONG-ZHE LIN ; Yang Y.-Y.; YU-YUN SHAO ; Shau W.-Y.; Kuo R.N.C.; CHIH-HSIN YANG ; Lai M.-S. | Oncology | 22 | 18 | |
12 | 2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
13 | 2010 | Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors | CHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T. | Journal of Thoracic Oncology | 26 | 22 | |
14 | 2009 | EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment | Huang C.-L.; CHIH-HSIN YANG ; KUN-HUEI YEH ; Hu F.-C.; KUAN-YU CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; ANN-LII CHENG ; PAN-CHYR YANG | Lung Cancer | 43 | 36 | |
15 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
16 | 2008 | Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy | CHIH-HSIN YANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; Hu F.-C.; Tsai M.-C.; KUAN-YU CHEN ; ZHONG-ZHE LIN ; Huang C.-J.; CHIA-TUNG SHUN ; Huang C.-L.; Bean J.; ANN-LII CHENG ; Pao W.; PAN-CHYR YANG | Journal of Clinical Oncology | 240 | 224 | |
17 | 2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 29 | 26 |